



Supplementary Figures.

Supplementary Figure 1


A



B










C



Supplementary Figure 1. Negative control was achieved by the application of anti-rabbit IgG following the same staining protocol (Dako, polyclonal antirabbit immunoglobulins HRP, REF: P0447, LOT:41236467, 1:1000) in breast cancer tumours **A** and **B** as well as Kidney tissue **C**.

Supplementary Figure 2



Supplementary Figure 2. INCENP mRNA expression and its association with copy number variations, clinicopathological parameters and molecular subtypes in METABRIC cohort.

A. INCENP and gene copy number variations

B. INCENP and Nottingham prognostic index.

C. INCENP and tumour size.

D. INCENP and TP53 mutation status

E. INCENP and lymph node stage


F. INCENP and tumour grade

G. INCENP and PAM50 BC subtypes


in the METABRIC cohort using one-way analysis of variance with the post-hoc Tukey test.

Supplementary Figure 3


Expression of INCENP in BRCA based on Sample types




Expression of INCENP in BRCA based on TP53 mutation status




Expression of INCENP in BRCA based on breast cancer subclasses




Expression of INCENP in BRCA based on Histologic subtypes



Expression of INCENP in BRCA based on nodal metastasis status








Expression of INCENP in BRCA based on patient's age



Supplementary Figure 3. INCENP mRNA expression and its association with clinicopathological parameters and molecular subtypes

- A. INCENP expression in normal and tumour tissue.
- B. INCENP and TP53 mutation status
- C. INCENP and PAM50 BC subtypes.
- D. INCENP and Histological subtypes.
- D. INCENP and lymph node stage.
- E. INCENP and tumour grade in the TCGA cohort.

Supplementary Figure 4



Supplementary Figure 4. INCENP mRNA expression against Breast Cancer Specific Survival (BCSS) in

A. All cases,

B. Luminal BC.

C. Triple-negative BC.


D. Human epidermal growth factor receptor 2 (HER2 +) tumours.

E. Basal Subtype, in the METABRIC cohort


Supplementary Figure 5

A


INCENP mRNA Expression TCGA

**B**


INCENP mRNA Expression TCGA

**C**


INCENP mRNA Expression TCGA

**D**

INCENP mRNA Expression TCGA


**E**

INCENP mRNA Expression TCGA




Supplementary Figure 5. INCENP mRNA expression and Breast Cancer Specific Survival (BCSS) in A. All cases,
B. Triple-negative tumours
C. Human epidermal growth factor receptor 2 (HER2 +) tumours.
D. (ER)-positive tumours
E. ER-negative tumours. .
in the TCGA cohort

Supplementary Figure 6



Patients at risk:

	3 739	3 309	2 739	2 126	1 588	1 131	684	(Events)
—	2 552	2 129	1 708	1 314	981	703	441	(812)



Number at risk

low	256	189	118	30	5	0
high	769	556	327	100	13	1

Supplementary Figure 6. INCENP mRNA expression and Breast Cancer Specific Survival (BCSS) in **A** the Breast Cancer Gene Expression Miner v4.3 database and **B** the Kaplan–Meier plotter.